ZKY 003
Alternative Names: ZKY-003Latest Information Update: 01 Feb 2023
At a glance
- Originator Zhaoke Ophthalmology Limited
- Developer Lee's Pharmaceutical; Zhaoke Ophthalmology Limited
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 01 Feb 2023 No development reported - Phase-III for Eye disorders in China (Ophthalmic) (Zhaoke Ophthalmology pipeline, February 2023) (Lee's Pharmaceutical pipeline, February 2023)
- 10 Dec 2020 Phase-III clinical trials in Eye disorders in China (Ophthalmic) before December 2020 (Lee's Pharmaceutical pipeline, December 2020)